Mid-stage win propels OS Therapies toward registration bid

16 January 2025

OS Therapies (NYSE-A: OSTX) has reported positive data from a Phase IIb trial evaluating OST-HER2, a HER2-targeted immunotherapy.

The therapy is being tested for people with fully resected, lung metastatic osteosarcoma, a kind of cancer that typically arises in the bone and which most commonly affects children and younger adults.

In some cases, osteosarcoma can spread to the lungs. There are currently no approved treatments specifically targeting this condition, and the outlook for affected patients is generally poor.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight





More Features in Biotechnology